论文部分内容阅读
目的探讨国产多烯紫杉醇(DC)及国产吉西他滨(GC)分别联合顺铂(DDP)治疗晚期非小细胞肺癌(NSCLC)疗效及不良反应。方法采用随机对照的方法观察40例 NSCLC 患者经两个方案(DC 组19例,GC组21例)治疗后的缓解率(RR)、疾病进展时间(TTP)、中位生存时间(MST)。结果 DC 组无完全缓解(CR),部分缓解(PR)8例,RR 42.1%,TTP4.7个月,MST11.3个月。GC 组 CR 1例,PR9例,RR47.7%,TTP4.6个月,MST10.6个月。两组疗效比较差异无显著性意义(P=0.71)。DC 组不良反应以粒细胞下降为主,GC 组不良反应以乏力和血小板降低为主,两组均可耐受,无治疗相关性死亡。结论 DC 和 GC 分别联合 DDP 治疗晚期NSCLC 具有较好的耐受性和较高的临床缓解率。
Objective To investigate the efficacy and adverse reactions of domestic docetaxel (DC) and domestic gemcitabine (GC) combined with cisplatin (DDP) in the treatment of advanced non-small cell lung cancer (NSCLC). Methods The RR, TTP and MST of 40 patients with NSCLC treated by two protocols (19 in DC group and 21 in GC group) were observed by randomized controlled trial. Results In the DC group, there was no complete remission (CR), partial remission (PR) in 8 cases, RR 42.1%, TTP in 4.7 months and MST in 11.3 months. GC group 1 CR, PR 9 cases, RR 47.7%, TTP4.6 months, MST10.6 months. There was no significant difference between the two groups (P = 0.71). Adverse reactions of DC group were mainly neutrophil. Adverse reactions of GC group were mainly fatigue and thrombocytopenia. Both groups were tolerated without treatment-related death. Conclusions Both DC and GC combined with DDP have better tolerability and higher clinical remission rate in advanced NSCLC.